Effect of Rivaroxaban vs Enoxaparin on Major Cardiac Adverse Events and Bleeding Risk in the Acute Phase of Acute Coronary Syndrome: The H-REPLACE Randomized Equivalence and Noninferiority Trial

IMPORTANCE: Parenteral enoxaparin is a preferred anticoagulant used in the acute phase for patients with acute coronary syndrome (ACS). The safety and efficacy of short-term low-dose rivaroxaban in this clinical setting remain unknown. OBJECTIVE: To compare the safety and efficacy of rivaroxaban vs...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Shenghua, Xiao, Yichao, Zhou, Chonglun, Zheng, Zhaofen, Jiang, Weihong, Shen, Qiang, Zhu, Can, Pan, Hongwei, Liu, Changhui, Zeng, Gaofeng, Ge, Liangqing, Zhang, Yumin, Ouyang, Zewei, Fu, Guang, Pan, Gang, Chen, Feng, Huang, Lihong, Liu, Qiming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9918885/
https://www.ncbi.nlm.nih.gov/pubmed/36763358
http://dx.doi.org/10.1001/jamanetworkopen.2022.55709

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9918885/
https://www.ncbi.nlm.nih.gov/pubmed/36763358
http://dx.doi.org/10.1001/jamanetworkopen.2022.55709

Ejemplares similares